SCOTTSDALE, Ariz., Sept. 17, 2015 (GLOBE NEWSWIRE) -- Avant Diagnostics, Inc.(OTCQXB:AVDX) (“Avant”) has engaged Goal Capital Inc. (“Goal Capital”) to provide a comprehensive strategic investor relations program on behalf of Avant. Goal Capital is an outsourced investor relations and consulting firm with experience in creating value and exposure for small- to mid-cap companies. Gregg Linn the President and CEO of Avant commented “We are thrilled that Goal Capital is part of our professional team. We continue to make progress toward Food and Drug Administration approval of OvaDx®, our proprietary diagnostic test for the early detection of ovarian cancer. Goal Capital has experience working with small cap health care/biotech companies and we welcome the opportunity to have Goal Capital assist us with telling our story to the investing public.”
About Avant Diagnostics, Inc.
Avant is a medical diagnostic technology company that specializes in first large panel biomarker screening. Our first test, OvaDx® detects for pre-symptomatic ovarian cancer. OvaDx® is a sophisticated microarray-based test that measures the activation of the immune system in blood samples in response to early stage ovarian tumor cell development. Pre-clinical research studies with OvaDx® indicate high sensitivity and specificity for all types and stages of ovarian cancer including stage IA-IV borderline serous, clear cell, endometrioid, mixed epithelial, mucinous, serous, and ovarian adenocarcinoma. Upon FDA 510K approval, Avant Diagnostics intends to sell or license OvaDx® as a diagnostic test for women seeking greater wellness and for women in the elevated risk category for ovarian cancer. Avant intends to utilize its public company stage to expand its portfolio of diagnostic tests in the future.
Safe Harbor Statement
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend,” among others. These forward-looking statements are based on Avant’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties with respect to lengthy and expensive clinical trials, that results of earlier studies and trials may not be predictive of future trial results; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. There are no guarantees that future clinical trials discussed in this press release will be completed or successful, or that any product will receive regulatory approval for any indication or prove to be commercially successful. Avant does not undertake an obligation to update or revise any forward-looking statement except as required by law. Investors should read the risk factors set forth in Avant’s Form 8-K filed with the Securities and Exchange Commission on January 14, 2015, as amended on January 16, 2015, and other periodic reports filed with the Securities and Exchange Commission.
CONTACT: Avant Diagnostics Gregg Linn, 480-478-6660 President/CEO glinn@avantdiagnsotics.com www.avantdiagnostics.com Or Goal Capital Inc., Investor Relations Danny Gravelle Tel 949-305-5093 contact@goalcapital.net Help employers find you! Check out all the jobs and post your resume.
